Individualized tacrolimus dosing based on time of day
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether giving tacrolimus at a time of day matched to each patient's body clock can improve safety and effectiveness after a kidney transplant. It may help recipients maintain stable drug levels with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You had your first kidney transplant, either from a living or deceased donor
- You are more than 3 months after the transplant and your kidney function is stable
- You take a standard combination of three anti-rejection drugs, including tacrolimus, mycophenolate, and a steroid
- Your tacrolimus dose and blood levels have been stable and you are not currently being treated for rejection
- You are not pregnant or planning pregnancy and do not have active infections or severe stomach issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
This study tests a personalized approach to dosing tacrolimus (an anti-rejection medicine) in children who have had a kidney transplant. By using each child's own data, doctors hope to find the best dose to keep the transplanted kidney healthy and avoid side effects.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
Hear when a new End Stage Renal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.